The shareholders of Medartis Holding AG (SIX: MED) today approved all the substantive proposals of the Board of Directors with significant majority exceeding 94.0%. All members of the Board of…
Medartis today reported total sales of CHF 224.8 million for the full year 2024, representing growth of 8.5% at constant exchange rates (CER). Core sales increased 11.7% and reached CHF 219.6 million.…
The New Medartis Global Website Is Live! We are thrilled to introduce our brand-new Medartis website—a significant step in our customer experience! This platform is more than just a redesign; it’s a…
We are pleased to announce that David Thoni will join Medartis as the new US President starting January 6, 2025. David will lead the US team as we advance on our journey to deliver innovative…
Medartis today announced that its Board has appointed Matthias Schupp to the position of CEO, joining Medartis by the beginning of November. Matthias will succeed Christoph Brönnimann, who will ensure…
The new Scaphoid System 1.5-3.0 sets new standards: Additional scaphoid plates and a dedicated container - including CCS – offer extended options for the treatment of scaphoid non-unions and…
The shareholders of Medartis Holding AG (SIX: MED) today approved all the substantive proposals of the Board of Directors with a clear majority of more than 94.8%. All members of the Board of…
Making a significant step forward, Medartis launches the new Mid- and Hindfoot 2.8/3.5 and the Fusion 3.5 System as well as the expansion of the Hallux and Midfoot 2.8 System in certain countries.
